Search clinical trials for: EGFR TKI

Total 1890 results

Assiut University

Not yet recruiting

Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI

CML, Chronic Phase
Daping Hospital and the Research Institute of Surgery...

Not yet recruiting

The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC

Non Small Cell Lung Cancer | EGFR Gene Mutation | Non-small Cell Lung Cancer Stage IV | Non Small Cell Lung Cancer Stage IIIA
SWOG Cancer Research Network
National Cancer Institute (NCI)

Not yet recruiting

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Lung Non-Small Cell Carcinoma
Wageningen University
Next Food Collective (previously TKI agri-food program and TiFN, Top Institute...

Recruiting

Impact of the Eating Rate of Ultra-processed Foods on Dietary Intake Behavior and Metabolic Responses

Eating Rate

Netherlands
University Hospitals of Derby and Burton NHS Foundation...

Not yet recruiting

Multimorbidity and Sarcopenia Feasibility Study in Chronic Kidney Disease (MaSS-CKD)

Chronic Kidney Diseases | Sarcopenia
Samsung Medical Center

Not yet recruiting

Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment

Non-Small Cell Lung Cancer Metastatic

Korea, Republic of
Kunming Medical University

Recruiting

A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

China
University of Turin, Italy
Azienda Ospedaliera Città della Salute e della Scienza di Torino

Recruiting

Development of a Fluorescent Visualization System for Non-visible Lung Cancer Nodules (RECOGNISE)

Lung Cancer | EGFR | Cetuximab | Video-assisted Thoracic Surgery

Italy
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

Metastatic Colorectal Adenocarcinoma | Refractory Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8

United States
Nanjing Sanhome Pharmaceutical, Co., Ltd.

Recruiting

SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations

Non-small Cell Lung Cancer

China
St. Joseph's Hospital and Medical Center, Phoenix
Barrow Neurological Institute; Ivy Brain Tumor Center

Recruiting

Study of BDTX-1535 in Recurrent High-Grade Glioma (HGG) Participants With EGFR Alterations or Fusions

High Grade Glioma

United States
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Non-small Cell Lung Cancer (NSCLC)

China, Taiwan, United States, Australia, Israel, Hong Kong, Chile, Korea, Republic of, Canada, Malaysia, Thailand, Brazil
Sun Yat-sen University

Recruiting

bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma

Liver Diseases | Hepatocellular Carcinoma | Immunotherapy | Sintilimab | Lenvatinib

China
Jonathan Riess
National Cancer Institute (NCI)

Not yet recruiting

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
AstraZeneca

Recruiting

OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain (OSIREAL)

Non-small Cell Lung Cancer

Spain
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator...

Not yet recruiting

Pharmacogenomics IND EXEMPT SNP Clinical Study - Crizotinib and Single Nucleotide Polymorphisms (Drugs-SNPs)

Non-Small Cell Lung Cancer

United States
Sun Yat-sen University

Recruiting

bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

Liver Diseases | Hepatocellular Carcinoma | Immunotherapy | Camrelizumab | Lenvatinib

China
Beijing 302 Hospital

Recruiting

Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC

Liver Neoplasms

China
University of North Carolina, Chapel Hill
Bayer

Recruiting

The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study

Kidney Transplant; Complications

United States
Fujian Cancer Hospital

Recruiting

Radiotherapy Combined With TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma

Stage IIIA Hepatocellular Carcinoma

China
Intergroupe Francophone de Cancerologie Thoracique

Recruiting

A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19) (ROSIE)

Non Small Cell Lung Cancer | EGFR Activating Mutation | EGFR L858R | EGFR DEL19

France
Haisco Pharmaceutical Group Co., Ltd.

Recruiting

Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation

NSCLC

China
Qianfoshan Hospital

Recruiting

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Advanced Non-small Cell Lung Cancer

China
Scorpion Therapeutics, Inc.

Recruiting

First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Non-Small Cell Lung Cancer | NSCLC | EGFR/HER2 Exon 20 Insertion Mutation

United States, Taiwan
Betta Pharmaceuticals Co., Ltd.

Recruiting

Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations

Non-Small Cell Lung Cancer | Adjuvant Therapy | EGFR Sensitive Mutation

China
RenJi Hospital
Shanghai Zhongshan Hospital; Ruijin Hospital

Recruiting

A Study of Cadonilimab（AK104） Plus Lenvatinib in Previous Immunotherapy Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy

China
First Affiliated Hospital, Sun Yat-Sen University

Not yet recruiting

Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment

Renal Cell Carcinoma
Convalife (Shanghai) Co., Ltd.

Not yet recruiting

Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations (CVL009-2001)

NSCLC

China
Kura Oncology, Inc.
Mirati Therapeutics Inc.

Recruiting

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (FIT-001)

Non Small Cell Lung Cancer (NSCLC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Colorectal Cancer (CRC) | Clear Cell Renal Cell Carcinoma (ccRCC) | Solid Tumors With HRAS Alterations

United States
Tianjin Medical University Second Hospital

Recruiting

Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors

Solid Tumor | EGFR Amplification

China
Yonsei University

Not yet recruiting

Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy (CHAMELEON)

Non Small Cell Lung Cancer

Korea, Republic of
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation

Non-Small Cell Lung Cancer、EGFR Sensitive Mutation

China
Avistone Biotechnology Co., Ltd.

Recruiting

A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC) (Kannon)

Non-Small-Cell Lung Cancer

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) With Osimertinib for the Treatment of Patients With Oligoprogressive EGFR Positive Non-small Cell Lung Carcinoma

Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8

United States
Teligene US

Recruiting

A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

Non-small Cell Lung Cancer

United States
Centro de Tratamiento e Investigación sobre Cáncer...

Not yet recruiting

Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO) (CULTRO)

Non Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Exon 19 Deletion | EGFR G719X | EGFR Exon 21 Mutation

Colombia
Sun Yat-sen University

Recruiting

Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC

Non-small Cell Lung Cancer

China
InxMed (Shanghai) Co., Ltd.

Recruiting

IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

NSCLC

China
Laibin People's Hospital

Not yet recruiting

Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer

Lung Cancer Stage III
Hunan Province Tumor Hospital

Not yet recruiting

A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer

NSCLC

China
Shanghai Zhongshan Hospital
Ningbo No. 1 Hospital; Shanghai Minhang Central Hospital; Xuhui Central Hospital... and other collaborators

Not yet recruiting

Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC

Non-Small Cell Lung Cancer
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator...

Not yet recruiting

Pharmacogenomics IND EXEMPT SNP Clinical Study - Alectinib and Single Nucleotide Polymorphisms (Drugs-SNPs)

Non-small Cell Lung Cancer

United States
M.D. Anderson Cancer Center
Eli Lilly and Company; BioMed Valley Discoveries, Inc

Recruiting

Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

Metastatic Colorectal Cancer

United States
Seagen Inc.

Recruiting

A Study of SGN-EGFRd2 in Advanced Solid Tumors

Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Squamous Cell Carcinoma of the Head and Neck | Pancreatic Ductal Adenocarcinoma

United States
Taiho Oncology, Inc.

Recruiting

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) (REZILIENT3)

Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation

United States, Spain, Canada, Italy, Israel, Japan, United Kingdom, Korea, Republic of, Germany, France, Turkey, Belgium, Netherlands, Philippines, Poland, Singapore
Taiho Oncology, Inc.

Recruiting

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. (REZILIENT2)

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

United States, Japan, Spain, France, Australia, Italy, Korea, Republic of, United Kingdom, Canada, Germany, Turkey, Hong Kong
Peking University People's Hospital
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation

EGFR Positive Non-small Cell Lung Cancer | Non Squamous Non Small Cell Lung Cancer
University Hospital, Clermont-Ferrand
Centre Hospitalier Universitaire de Saint Etienne; Central Hospital, Nancy,... and other collaborators

Recruiting

Chronic Myeloid Leukemia (CML) Real-Life Database

Chronic Myeloid Leukemia (CML)

France
Guangdong Association of Clinical Trials
Guangdong Provincial People's Hospital

Recruiting

Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment

Small-cell Lung Cancer

China
TYK Medicines, Inc

Recruiting

TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

NSCLC | Brain Metastases | EGFR Activating Mutation

China

Search clinical trials for: EGFR TKI

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations